Cargando…

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study

The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer immunotherapy. The related literature shows the explosive growth trends due to the promising outcomes of tumor regression. The present study aimed to p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yiting, Jiang, Liqing, Wen, Ti, Guo, Xiaoyu, Shao, Xinye, Qu, Hui, Chen, Xi, Song, Yujia, Wang, Fang, Qu, Xiujuan, Li, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418110/ https://www.ncbi.nlm.nih.gov/pubmed/34489691 http://dx.doi.org/10.3389/fphar.2021.670900

Ejemplares similares

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
por: Liu, Yanhao, et al.
Publicado: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)

Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study
por: Lai, Sicen, et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer
por: Tang, Zhen-Chu, et al.
Publicado: (2023)

PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis
por: Guo, Xiaoyu, et al.
Publicado: (2022)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

Corrigendum: Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer
por: Tang, Zhen-Chu, et al.
Publicado: (2023)

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis
por: Xu, Yantao, et al.
Publicado: (2022)

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade
por: Rossi, Alessandra, et al.
Publicado: (2020)

CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
por: Magkouta, Sophia Fotiou, et al.
Publicado: (2021)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
por: Yang, Yuanyuan, et al.
Publicado: (2022)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy
por: Liu, Zefan, et al.
Publicado: (2023)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis
por: Zhang, Yue, et al.
Publicado: (2023)

Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
por: Trommer, Maike, et al.
Publicado: (2019)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
por: Rigo, Valentina, et al.
Publicado: (2017)

Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review
por: Tavares, Dione Fernandes, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m1hg7if19o0rv3m6pnrgbevht3